Michal Mego, Prof
National Cancer Institute (NCI) · National Cancer Institute, Slovakia
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michal Mego, Prof as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:01 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07121322 · Dornase Alfa and Cisplatin in Refractory Germ Cell Cancer.National Cancer Institute, Slovakia · recruiting · Refractory Germ Cell Tumors, Dornase Alfa · study chair
- N/ANCT04691284 · Microbiome in Cancer Patients With High Dose Chemotherapy With Stem Cell TransplantationNational Cancer Institute, Slovakia · recruiting · Hematologic Neoplasms · study chair
- Ph2NCT04265274 · Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.National Cancer Institute, Slovakia · withdrawn · Metastatic Breast Cancer · study chair
- Ph2NCT03950830 · Disulfiram and Cisplatin in Refractory TGCTs.National Cancer Institute, Slovakia · completed · Germ Cell Tumor · principal investigator
- Ph2NCT03403777 · Avelumab in Refractory Testicular Germ Cell Cancer.National Cancer Institute, Slovakia · completed · Testicular Neoplasms, Neoplasms, Germ Cell and Embryonal, Neoplasms · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:01 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in breast cancer.